SCHEMBL5458431

SCHEMBL5458431

NC(=O)c1c(NC(=O)c2cccc(F)c2)sc2c(Cl)c(O)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
PKM P14618 1/20 0.43
KCNQ3 O43525 2/20 0.42
KCNQ2 O43526 2/20 0.42
KCNQ5 Q9NR82 1/20 0.42
PARP1 P09874 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KCNE1 P15382 1/20 0.41
KCNQ1 P51787 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
CYP1A2 P05177 1/20 0.40
KCNK3 O14649 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453155 0.86 TAS1R3 (0.43) FLT3SMN1; SMN2NPC1RAB9AKCNQ3
SCHEMBL5466113 0.84 FLT3 (0.42) FLT3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5456366 0.83 FLT3 (0.52) FLT3NPC1RAB9AALDH1A1PKM
SCHEMBL5458492 0.83 NPC1 (0.48) NPC1RAB9AALDH1A1TP53KCNMA1
SCHEMBL5455924 0.82 FLT3 (0.54) FLT3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5450952 0.81 RHOC (0.42) FLT3MEN1KMT2AGAAHDAC6
SCHEMBL5460181 0.81 GRIN2C (0.44) FLT3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5445078 0.79 CFTR (0.46) FLT3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5447561 0.79 FLT3 (0.43) FLT3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5447136 0.77 FLT3 (0.44) FLT3SMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885SMN1; SMN2 2157/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.